about
The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UKClinical pharmacology and regulatory consequences of GnRH analogues in prostate cancerContemporary role of androgen deprivation therapy for prostate cancerPregnane X receptor as a therapeutic target to inhibit androgen activity.Controversies surrounding androgen deprivation for prostate cancer.Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort.A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer.Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.Indirect androgen doping by oestrogen blockade in sports.Adverse effects of androgen deprivation therapy for prostate cancer: prevention and managementManagement of advanced prostate cancer: can we improve on androgen deprivation therapy?Degarelix for prostate cancer.Degarelix and its therapeutic potential in the treatment of prostate cancer.A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma.Differing levels of testosterone and the prostate: a physiological interplay.Pharmacotherapeutic management of locally advanced prostate cancer: current status.Androgen deprivation therapy: past, present and future.Landmarks in hormonal therapy for prostate cancer.Novel agents in the management of castration resistant prostate cancer.Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27)Challenges in diagnosis and treatment of a cervical spinal cord injury patient with melanoma, adenocarcinoma, and hepatic and osteolytic metastases: need to implement strategies for prevention and early detection of cancer in spinal cord injury pati[Prostate carcinoma and testosterone: risks and controversies].The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy.Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics.Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
P2860
Q28072710-8C060796-AEDD-4445-8898-2021513A3697Q34104391-11BFA6AD-A43A-4AE3-A617-C52ECD25F618Q34211155-FE797248-B8CD-4BE2-9B93-75BC9A3009BCQ34392652-AD707876-5D16-4AE3-9925-A1505A68F068Q34849222-1A6D26CF-AF35-4FC3-83FE-8902E481C42EQ35161023-9273BADB-0E27-45C4-AC13-71C23EAAD61AQ35680629-AA79B123-1C94-40AA-90F8-CABF8DC5C58EQ36677464-7A396F88-B09D-42C3-9707-B575899A4757Q36736110-92D7AEA4-2A8B-4C22-8ABC-CF0A6A39FAEAQ37105407-58B4D0B1-02FA-4862-BA20-343CA0EE00BAQ37108818-F8071908-C263-44CC-9677-4DC1D4179295Q37488225-D9DD232C-194B-4B06-A155-8F48020F380EQ37510637-A7ED6D26-15F9-4C30-916F-061DFE970E39Q37727423-0AD3E238-FE00-4149-8B4D-6553A1125A08Q37883014-0D71D63A-A96A-4A10-A8BC-760305099456Q37888666-42227FD5-A5FC-49D4-A57A-B6F656843BC2Q38016530-E791F564-E9B1-4F05-9CA9-599C3E831489Q38050466-D98E31D9-9CB0-49DC-8985-3924601E0BA5Q38209656-23829780-708E-4DE8-AA01-1736AA34BDA4Q38798811-3E4E0BE2-6329-40C8-BB45-452A29596D42Q41600644-5D7A50C8-9BD4-42EE-BF5B-0C6CF354EB73Q42380019-7DF9979A-7996-4CEA-8081-A9001B976760Q43176627-94E97D2E-4BED-484E-8BE5-E8650A12BD9EQ46720614-3230C7A8-9B95-46E2-9A3D-5D61D0AAEA83Q50020219-BD4484EF-1D0F-4276-806B-E793C7EB2B3EQ51786275-70AA82D8-0948-4162-BDBA-EE31FCC61F2E
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Is the flare phenomenon clinically significant?
@ast
Is the flare phenomenon clinically significant?
@en
Is the flare phenomenon clinically significant?
@nl
type
label
Is the flare phenomenon clinically significant?
@ast
Is the flare phenomenon clinically significant?
@en
Is the flare phenomenon clinically significant?
@nl
prefLabel
Is the flare phenomenon clinically significant?
@ast
Is the flare phenomenon clinically significant?
@en
Is the flare phenomenon clinically significant?
@nl
P1433
P1476
Is the flare phenomenon clinically significant?
@en
P2093
P356
10.1016/S0090-4295(01)01235-3
P407
P433
P577
2001-08-01T00:00:00Z